Evidence map›Paper›PMID 35725505›Full record

ReviewStem cell research & therapy2022

Chronic obstructive pulmonary disease and asthma: mesenchymal stem cells and their extracellular vesicles as potential therapeutic tools.

Hossein Abbaszadeh, Farzaneh Ghorbani, Sanaz Abbaspour-Aghdam, Amin Kamrani, Hamed Valizadeh, Mehdi Nadiri, Armin Sadeghi, Karim Shamsasenjan, Farhad Jadidi-Niaragh, Leila Roshangar and 1 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Stem cell research & therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Hossein AbbaszadehStem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Farzaneh GhorbaniStem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Sanaz Abbaspour-AghdamStem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Amin KamraniStem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Hamed ValizadehTuberculosis and Lung Disease Research Center of Tabriz University of Medical Sciences, Tabriz, Iran.
Mehdi NadiriTuberculosis and Lung Disease Research Center of Tabriz University of Medical Sciences, Tabriz, Iran.
Armin SadeghiTuberculosis and Lung Disease Research Center of Tabriz University of Medical Sciences, Tabriz, Iran.
Karim ShamsasenjanStem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Farhad Jadidi-NiaraghImmunology Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Leila RoshangarStem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. lroshangar@yahoo.com.
Majid AhmadiStem Cell Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. ahmadi.m@tbzmed.ac.ir.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic lung diseases, such as chronic obstructive pulmonary disease (COPD) and asthma, are one of the most frequent causes of morbidity and mortality in the global. COPD is characterized by progressive loss of lung function through inflammation, apoptosis, and oxidative stress caused by chronic exposure to harmful environmental pollutants. Airway inflammation and epithelial remodeling are also two main characteristics of asthma. In spite of extensive efforts from researchers, there is still a great need for novel therapeutic approaches for treatment of these conditions. Accumulating evidence suggests the potential role of mesenchymal stem cells (MSCs) in treatment of many lung injuries due to their beneficial features including immunomodulation and tissue regeneration. Besides, the therapeutic advantages of MSCs are chiefly related to their paracrine functions such as releasing extracellular vesicles (EVs). EVs comprising exosomes and microvesicles are heterogeneous bilayer membrane structures loaded with various lipids, nucleic acids and proteins. Due to their lower immunogenicity, tumorigenicity, and easier management, EVs have appeared as favorable alternatives to stem cell therapies. Therefore, in this review, we provided an overview on the current understanding of the importance of MSCs and MSC-derived EVs from different sources reported in preclinical and clinical COPD and asthmatic models.

Indexed as

AsthmaExtracellular VesiclesMesenchymal Stem CellsPulmonary Disease, Chronic ObstructiveHumansInflammationAsthmaCOPDEmphysemaExosomesLung diseasesMesenchymal stromal cellsMicrovesiclesRegeneration

Identifiers

PMID35725505
PMCPMC9208161

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.